All Stories

  1. Serum miR-4530 sensitizes breast cancer to neoadjuvant chemotherapy by suppressing RUNX2

    Article • Cancer Management and Research, October 2018, Dove Medical Press

    Xiao-Xiao Wanf, Lin peiyang